Peter Buhl Jensen
Chief Executive Officer at CHOSA ONCOLOGY AB
Profile
Peter Buhl Jensen founded Topotarget A in 2000, where he worked as Chief Executive Officer from 2000 to 2010, Allarity Therapeutics Europe ApS in 2012, where he is working as Chief Executive Officer, Oncology Venture Sweden AB in 2012, where he worked as Chief Executive Officer, and Allarity Therapeutics A in 2004, where he worked as Chief Executive Officer & Director from 2012 to 2019.
Dr. Jensen also currently works at Symbion A, as Chief Executive Officer & Director from 2010, AntiAnthra ApS, as Chief Executive Officer from 2012, Chosa Oncology AB, as Chief Executive Officer, Medical Prognosis Institute, Inc., as Chairman, Amniotics AB, as Chairman from 2021, Symbion Fonden, as Director, Cobis A, as Director, the University of Copenhagen, as Professor from 2012, and Buhl Krone Holding ApS, as Owner.
Dr. Jensen also formerly worked at Medical Prognosis Institute A, as Chief Executive Officer & Director, Liplasome Pharma ApS, as Chief Executive Officer, Cytoguide ApS, as Chairman, Ranger Biotechnologies A, as Chairman, Affibody AB, as Director, LiPlasome Pharma A, as Director in 2012, Symbion Management A, as Director, Aprea Therapeutics AB, as Director, Axelar AB, as Director, Wntresearch AB, as Director, Respiratorius AB, as Director, 4 Best Invest ApS, as Director, IT-Væksthus A, as Director, Egetis Therapeutics AB, as Director, Medicon Valley Alliance FMBA, as Director, Renovaro Biosciences Denmark ApS, as Director, Vecata Ejendomme A, as Director, Valerio Therapeutics SA, as Principal, and Alborg Sygehus, as Chief Oncologist-Oncology Department.
Dr. Jensen received his doctorate degree from the University of Copenhagen.
Peter Buhl Jensen active positions
Companies | Position | Start |
---|---|---|
AMNIOTICS AB | Chairman | 2021-04-14 |
CHOSA ONCOLOGY AB | Chief Executive Officer | - |
Cobis A/S
Cobis A/S Miscellaneous Commercial ServicesCommercial Services Cobis A/S provides business support services. | Director/Board Member | - |
Symbion Fonden | Director/Board Member | - |
Medical Prognosis Institute, Inc. | Chairman | - |
Buhl Krone Holding ApS | Corporate Officer/Principal | - |
Allarity Therapeutics Europe ApS
Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Chief Executive Officer | 2011-12-31 |
Symbion A/S
Symbion A/S General GovernmentGovernment Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark. | Chief Executive Officer | 2009-12-31 |
University of Copenhagen | Corporate Officer/Principal | 2011-03-06 |
░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Former positions of Peter Buhl Jensen
Companies | Position | End |
---|---|---|
░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░ | ░░░░░░░░ | - |
░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Peter Buhl Jensen
University of Copenhagen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 6 |
---|---|
VALERIO THERAPEUTICS | Health Technology |
WNTRESEARCH AB | Health Technology |
Health Technology | |
EGETIS THERAPEUTICS AB | Health Technology |
AMNIOTICS AB | Health Technology |
CHOSA ONCOLOGY AB | Commercial Services |
Private companies | 25 |
---|---|
Affibody AB
Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden. | Commercial Services |
Topotarget A/S
Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
Symbion A/S
Symbion A/S General GovernmentGovernment Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark. | Government |
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Health Technology |
AntiAnthra ApS | |
Symbion Management A/S
Symbion Management A/S Investment ManagersFinance Symbion Management A/S is the subsidiary of Symbion A/S in Denmark. Headquartered in Copenhagen, Symbion is organized around facility rental, business development and education for an early professionalization of companies as well as arrangement of risk capital. | Finance |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | Health Technology |
4 Best Invest ApS
4 Best Invest ApS Financial ConglomeratesFinance Part of Bakodo ApS, 4 Best Invest ApS functions as an investment fund. The CEO of the Danish company is Hans-Henrik Horsted Eriksen. | Finance |
Ranger Biotechnologies A/S
Ranger Biotechnologies A/S Miscellaneous Commercial ServicesCommercial Services Mirrx Therapeutics A/S provides protein production technology. Its technology Blockmirs, is steric antisense blockers that bind to specific microRNA binding sites in target RNAs to thereby prevent microRNA binding to the same site. The company was founded by Hans Thorleif Møller on July 1, 2009 and is headquartered in Vejle, Denmark. | Commercial Services |
Medical Prognosis Institute A/S
Medical Prognosis Institute A/S BiotechnologyHealth Technology Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark. | Health Technology |
IT-Væksthus A/S | |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | Commercial Services |
Alborg Sygehus | |
Renovaro Biosciences Denmark ApS
Renovaro Biosciences Denmark ApS Miscellaneous Commercial ServicesCommercial Services Dandrit Biotech A/S conducts clinical research, trading, and manufacturing for the pharmaceutical industry. It focuses on research and development of medicines. The company was founded on April 1, 2001 and is headquartered in Hørsholm, Denmark. | Commercial Services |
Vecata Ejendomme A/S
Vecata Ejendomme A/S Real Estate DevelopmentFinance Part of Bagger-Sørensen Invest A/S, Vecata Ejendomme A/S engages in leasing of commercial real estate properties. The company is based in Vejle, Denmark. The CEO of the Danish company is Hans-Henrik Horsted Eriksen. | Finance |
Allarity Therapeutics Europe ApS
Allarity Therapeutics Europe ApS Pharmaceuticals: MajorHealth Technology Allarity Therapeutics Europe ApS operates as a pharmaceutical company that provides oncology products. The firm engages in diagnostics and drug development. The company was founded by Steen Meier Knudsen on August 1, 2012 and is headquartered in Hørsholm, Denmark. | Health Technology |
Medical Prognosis Institute, Inc. | |
Oncology Venture Sweden AB
Oncology Venture Sweden AB BiotechnologyHealth Technology Oncology Venture Sweden AB engages in research and development of anti-cancer drugs through its subsidiary Oncology Ventures ApS. It focuses on diagnostics and development of medicinal products for treatment of cancer. The company was founded by Peter Buhl Jensen, Steen Meier Knudsen, Nils Aage Brünner, and Ulla Hald Buhl on June 4, 2015 and is headquartered in Hørsholm, Denmark. | Health Technology |
Liplasome Pharma ApS
Liplasome Pharma ApS Pharmaceuticals: MajorHealth Technology Liplasome Pharma ApS operates as a biotech company focusing on oncology. It develops drug delivery technologies for anticancer market. The firm's drug delivery platform consists of a lipid based drug delivery system for the intravenous transportation of anticancer drugs and prodrugs. The company was founded in 2002 and is headquartered in Hoersholm, Denmark. | Health Technology |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Health Technology |
Symbion Fonden | |
Cobis A/S
Cobis A/S Miscellaneous Commercial ServicesCommercial Services Cobis A/S provides business support services. | Commercial Services |
Buhl Krone Holding ApS |
- Stock Market
- Insiders
- Peter Buhl Jensen